Navigation Links
Physician to Implant the CATANIA(TM) Coronary Stent System With Polyzene(R)-F to Treat Chronic Total Occlusion During 'Live' Case at the Paris Cardiovascular Interventions Course (Francophone) 2008
Date:10/1/2008

Research Shows New Class of Stent Effective in Preventing Thrombosis,

Restenosis, and Reocclusion

PARIS, Oct. 1 /PRNewswire/ -- CeloNova BioSciences, Inc., today announced that Masahiko Ochiai MD, Associate Professor, Division of Cardiology, Yokohama Hospital, Kanagawa, Japan has selected the CATANIA(TM) Coronary Stent System featuring NanoThin Polyzene(R)-F for treating a patient with a chronic total occlusion (CTO) during a live case symposium at the Paris Cardiovascular Interventions (Francophone) Congress. The CATANIA(TM) Coronary Stent System carries a CE Mark and is currently available for sale in Europe.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081001/CLW080-a )

(Logo: http://www.newscom.com/cgi-bin/prnh/20081001/CLW080LOGO-b )

Chronic total occlusion is defined as any artery where blood flow has been completely blocked for greater than 30 days. These types of lesions are exceptionally difficult to treat with percutaneous intervention (angioplasty) because of the challenges physicians face in crossing the lesion to move the catheter into place for proper stent deployment. The CATANIA(TM) Stent was selected for this live case because Polyzene(R)-F makes it highly lubricious and delivers low restenosis rates, excellent anti-thrombosis rates, and other clinical benefits that approach or, in some cases, may exceed those of DES, while addressing some of the significant ongoing concerns with current DES technology such as product cost, risk for thrombosis, and serious challenges associated with costly long-term dual anti-platelet therapy following treatment.

"The CATANIA(TM) Stent has superb pushability, trackability, and flexibility. You can feel that the Polyzene(R)-F surface is slicker than other stents," said Thierry Corcos, MD, Service de Cardiologie, Clinique Turin, Paris, France. "For the live case, we want to really test the CATANIA(TM) Stent's capabilities in a challenging anatomy, because of the clinical evidence that Polyzene(R)-F nanocoating prevents thrombosis, restenosis and reocclusion. Based on my experience, I believe the CATANIA(TM) Stent is an ideal choice for treating coronary artery disease, including chronic total occlusions."

The rapid-exchange, cobalt-chromium CATANIA(TM) Stent features a modified open-cell design and is available in 60 sizes in lengths from 8mm to 38mm and in diameters, from 2.0 to 4.0mm. The CATANIA(TM) Stent does not contain any drugs, off-loaded materials or biological substitutes. The proprietary nanothin, highly lubricious Polyzene(R)-F is a synthesized, inorganic, biocompatible polymer that is anti-thrombotic, anti-inflammatory, bacterial-resistant, and essentially cloaks the device's presence from the body to promote healthy endothelial cell growth without stimulating platelet activation. This unique combination of stent and surface treatment effectively creates a new and different class of stent that does not require long-term dual anti-platelet therapy.

"It is exceptionally gratifying that Dr. Corcos and Dr. Ochiai selected to showcase the abilities of the CATANIA(TM) Stent in such an important, and difficult-to-treat live case, because we design all of our products from the ground up using direct feedback from the physicians who use them," said Thomas A. Gordy, President and Chief Executive Officer, CeloNova BioSciences, Inc. "We are looking forward to presenting the CATANIA(TM) long-term, First-In-Man data on the world stage later this month during the Transcatheter Therapeutics (TCT) annual meeting in Washington, DC."

For more information about CeloNova BioSciences' products and Polyzene(R)-F technology, visit http://www.celonova.com .

About CeloNova BioSciences, Inc.

Headquartered in Newnan, near Atlanta, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are then enhanced by one of the Company's proprietary materials, Polyzene(R)-F. Polyzene(R)-F is highly lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant making it an ideal surface treatment for implanted medical devices. The Company's current products include its Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Other innovative devices are currently in the company's developmental pipeline. For more information, please visit http://www.celonova.com .

CONTACT: Robert J. Murphy

The Storch-Murphy Group

908-276-0777


'/>"/>
SOURCE CeloNova BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Diageo Sponsors Medical Society of the State of New Yorks Physicians Training Program
2. Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market
3. Top Health Care Economists and Physician-Innovators Discuss Value of Medical Technology at AdvaMed 2007 Conference
4. Cynthia Haines, M.D., Named Managing Editor of Physicians Briefing News Wire
5. Young Physicians Demanding Advanced Laparoscopic Energy Instruments
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
8. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
9. Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment
10. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
11. Hot Information for Physicians Treating Vasomotor Symptoms During the Menopausal Transition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... , ... The new and improved Oakton® pocket testers, from Cole-Parmer, stand up ... a new cap design that is versatile, functional and leakproof. They are ideal for ... water quality. , The Oakton pocket testers have many user-friendly and functional features. An ...
(Date:9/19/2017)... Sept. 19, 2017 ValGenesis Inc., the global ... pleased to announce the strategic partnership with VTI Life ... with validation services using the latest technology available in ... provide clients with efficient and cost-effective validation services using ... for the ValGenesis VLMS system. ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... technologies, today announced a partnership with Cytena GmbH to launch the CloneSelectâ„¢ Single-Cell ... real-time image analysis to isolate single cells and provide visual documentation of monoclonality ...
(Date:9/19/2017)... ... 2017 , ... Band-LOK, LLC, an orthopedic medical device innovation ... patents have been allowed by the USPTO on the proprietary Tether Clamp and ... explore additional clinically-relevant designs for both the implants and the instrumentation. I ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
Breaking Biology News(10 mins):